Corestemchemon Inc. (166480)

Overview

CORESTEMCHEMON Inc., originally known as Corestem, Inc., was established in 2003 and has since positioned itself as a pioneering bio-pharmaceutical entity in South Korea, dedicated to advancing the field of regenerative medicine through innovative stem cell therapies. The company aims to address the challenges of incurable diseases by developing and producing autologous bone marrow mesenchymal stem cell therapies. One of its flagship products, NEURONATA-R inj, has been developed for the treatment of amyotrophic lateral sclerosis (ALS), showcasing the company's commitment to tackling neurodegenerative disorders. CORESTEMCHEMON Inc. is exploring the potential of its technological advancements in stem cell therapy across a spectrum of diseases, including systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA). Situated in Seongnam, South Korea, the company remains at the forefront of bio-pharmaceutical innovation, driven by a mission to provide new hope for patients battling incurable diseases.

Products and Services

• NEURONATA-R inj:

  An autologous bone marrow mesenchymal stem cell therapy specifically developed for the treatment of amyotrophic lateral sclerosis (ALS). This groundbreaking therapy represents CORESTEMCHEMON Inc.'s dedication to combating neurodegenerative diseases by harnessing the regenerative capabilities of stem cells.

• Systemic Lupus Erythematosus (SLE) Therapy:

  A therapeutic product currently under development, aimed at treating SLE, an autoimmune disease where the body's immune system attacks its own tissues. CORESTEMCHEMON Inc. is exploring stem cell-based approaches to provide new treatment options for patients suffering from this debilitating condition.

• Multiple System Atrophy (MSA) Therapy:

  Another area of focus for CORESTEMCHEMON Inc. involves the development of stem cell therapies for the treatment of multiple system atrophy (MSA), a progressive neurodegenerative disorder. The company's work in this field underscores its commitment to addressing rare and challenging diseases with cutting-edge biomedical solutions.

• Cerebellar Ataxia (CA) Therapy:

  Engaged in the development of treatment options for cerebellar ataxia (CA), CORESTEMCHEMON Inc. is leveraging its expertise in stem cell therapy to combat this group of disorders characterized by coordination and balance issues. The company’s initiative in this area signifies its broadened approach towards tackling neurological diseases through innovative therapies.